Nine Months Ended

December 31, 2015

(unaudited)

($)

Year Ended

March 31, 2015

($)

Balance due from (to) Pharma and NDM at beginning of period

192,505

-

Amounts advanced to Pharma

-

567,633

Amounts received from Pharma

(239,717

)

(7,692

)

Reduction in prepayments to Pharma for clinical trials

(249,459

)

(257,441

)

Amounts invoiced by DDL to Pharma and NDM (sale of assets)

17,755

-

Amounts invoiced by Pharma to DDL and TCL

(226,148

)

(106,193

)

Expenses paid by Pharma on behalf of DDL and TCL

-

134

Intellectual Property costs paid by Pharma on behalf of DDL and TCL

-

(946

)

Foreign exchange differences

19,160

(2,990

)

Balance due from (to) Pharma and NDM at end of the period

(485,904

)

192,505